Miach Orthopaedics secures $40M to support its ACL tears implant

The Bear implant to treat a torn ACL [Image courtesy of Miach Orthopaedics]Miach Orthopaedics today announced that it’s closed on $40 million in financing to support expanded U.S. commercialization of its Bear implant to treat ACL tears.

The financing includes $30 million in Series B equity from lead investors Sectoral Asset Management and Endeavour Vision. Existing investors — including Amzak Health, Smith+Nephew, DSM Venturing and the NFL Players Association — also joined the funding round.

Additionally, Miach Orthopaedics has signed a $10 million venture debt term sheet with Silicon Valley Bank. The Westborough, Massachusetts–based company plans to close the loan shortly after the closing of the Series B.

Sectoral and Endeavour will have representatives on the Miach board of directors.

“Since launching our Bear implant in fall 2021, we’ve received tremendous interest from both surgeons and patients alike, who understand the benefits of heali…

Read more
  • 0

Miach Orthopaedics makes ACL tear implant commercially available in U.S.

Miach Orthopaedics announced today that it made the BEAR implant for treating anterior cruciate ligament (ACL) tears commercially available in the U.S.

Westborough, Massachusetts-based Miach designed the BEAR (Bridge-Enhanced ACL repair) implant to enable the healing of a patient’s torn ACL, shifting from the current standard of care that includes reconstruction that replaces the ACL with a graft.

According to a news release, the BEAR implant also received a Popular Science Best of What’s New Award for its representation of a significant step forward in health.

The BEAR implant restores ACL quality and size similar to the non-injured ACL to provide a faster recovery of muscle strength and better patient satisfaction around returns to sports. By eliminating the need for a graft, BEAR allows for patients to avoid needing a second wound site to heal and alleviates worries about donor graft quality or risk of disease.

Dr. Jonathan L. Glash…

Read more
  • 0